Is Ocugen Finally on the Way to Vaccine Revenue?

Is Ocugen Finally on the Way to Vaccine Revenue?

Last year, Ocugen (NASDAQ: OCGN) shares soared more than 700% over just a few days. The company signed an agreement to co-commercialize Bharat Biotech's coronavirus vaccine in the U.S. The companies later added rights in Canada to the agreement too. Bharat's product -- Covaxin -- already had gained emergency authorization in its home country of India.